Patents Assigned to Schering Corporations
  • Patent number: 7705019
    Abstract: In its many embodiments, the present invention provides a novel class of compounds of structural formula IA or IB where R1-R8 are as disclosed herein as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventors: Tze-Ming Chan, Kathleen Cox, Wenqing Feng, Michael W. Miller, Daniel Weston, Stuart W. McCombie
  • Patent number: 7705128
    Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-1?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventor: Jacqueline C. Timans
  • Patent number: 7705153
    Abstract: The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.
    Type: Grant
    Filed: February 2, 2005
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventors: Pauline C. Ting, Jianhua Cao, Youhao Dong, Eric J. Gilbert, Ying Huang, Joseph M. Kelly, Stuart McCombie, Neng-Yang Shih
  • Patent number: 7705127
    Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventors: Thomas E. Hesson, Hung V. Le, Yao Ma, Vincent S. Madison, Anthony F. Mannarino, Paul Reichert, Gerald W. Shipps, Jr., Corey O. Strickland, Shahriar Shane Taremi, Yaolin Wang, Rumin Zhang, Jose Duca
  • Patent number: 7700597
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Andrew W. Stamford, William J. Greenlee, Jay Weinstein
  • Patent number: 7700753
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
  • Patent number: 7700592
    Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Kevin D. McCormick, Christopher W. Boyce, Neng-Yang Shih, Chia-Yu Huang, Robert G. Aslanian, Salem Fevrier, Bo Liang, Rong-qiang Liu, Ruiyan Liu, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Lisa Guise-Zawacki, Junying Zheng
  • Patent number: 7700601
    Abstract: Disclosed is a compound of the formula: and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered in combination with at least one addition pharmaceutically active ingredient.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Tin-Yau Chan, Brian A. McKittrick, Haiyan Pu, Liwu Hong, Andrew J. Prongay, Li Xiao, Mark A. McCoy
  • Patent number: 7700773
    Abstract: In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Alan K. Mallams, Vincent S. Madison, Kamil Paruch
  • Patent number: 7700603
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Zhaoning Zhu, Brian A McKittrick, Zhong-Yue Sun, Yuanzan C Ye, Johannes H Voigt, Corey Strickland, Elizabeth M. Smith, Andrew Stamford, William J. Greenlee, Robert Mazzola, John Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Tao Guo, Thuy X. H. Le, Kurt W. Saionz, Suresh D. Babu, Rachael C. Hunter, Michelle L. Morris, Gang Qian, Dawit Tadesse
  • Patent number: 7700728
    Abstract: The present invention provides novel materials and screening methods for identifying agonists and antagonists of cell receptors. Methods are disclosed for identifying agonists and antagonists using chimeric receptors comprising the extracellular ligand-binding domain of a first receptor fused with the transmembrane and intracellular domains of a second receptor containing an intracellular immunoreceptor tyrosine-based activation motif (ITAM).
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Elizabeth Esther Mary Bates, Estelle Merck, Odette de Bouteiller, Christophe Caux
  • Publication number: 20100093692
    Abstract: The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.
    Type: Application
    Filed: February 27, 2008
    Publication date: April 15, 2010
    Applicant: Schering Corporation Sechering-Plough Corporation
    Inventors: Robert G. Aslanian, Jean E. Lachowicz, Michael Y. Berlin, Joyce J. Hwa
  • Patent number: 7696317
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: April 13, 2010
    Assignee: Schering Corporation
    Inventor: Daniel M. Gorman
  • Publication number: 20100087499
    Abstract: The present invention provides formulations, kits and methods useful for treating cell proliferative disorder. In particular, the formulations, kits and methods include temozolomide (TMZ) in combination with a multi-targeted kinase inhibitor.
    Type: Application
    Filed: January 28, 2008
    Publication date: April 8, 2010
    Applicant: SCHERING CORPORATION
    Inventors: Yaolin Wang, Ming Liu, Walter Robert Bishop
  • Patent number: 7691856
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: April 6, 2010
    Assignees: Schering Corporation, Pharmacopeia, Inc.
    Inventors: Arthur G. Taveras, Jianhua Chao, Purakkattle J. Biju, Younong Yu, Cynthia J. Aki, J. Robert Merritt, Ge Li, John J. Baldwin, Gaifa Lai, Minglang Wu, Evan A. Hecker
  • Patent number: 7691373
    Abstract: Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: April 6, 2010
    Assignee: Schering Corporation
    Inventors: Jenny Valladeau, Odile Ravel, Elizabeth Esther Mary Bates, John Ford, Sem Saeland, Serge J. E. Lebecque
  • Patent number: 7687073
    Abstract: The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: March 30, 2010
    Assignee: Schering Corporation
    Inventor: Tsong-Toh Yang
  • Patent number: 7687631
    Abstract: This application discloses a novel process for the preparation of phosphonate esters useful as intermediates in the preparation of himbacine analogs, themselves useful as thrombin receptor antagonists. The chemistry taught herein can be exemplified by the following scheme: wherein R9 is selected from alkyl, aryl heteroaryl and arylalkyl groups having 1 to 10 carbon atoms, and R11 is selected independently for each occurrence from alkyl, aryl heteroaryl and arylalkyl groups having 1 to 10 carbon atoms and hydrogen, X2 is Cl, Br, or I; X3 is selected from Cl and Br; and PdLn is a supported palladium metal catalyst or a soluble heterogeneous palladium catalyst. The L-derivatizing reagent is a moiety which converts the alcohol functional group of compound 137D to any leaving group which can be displaced by a triorgano-phosphite phosphonating agent.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: March 30, 2010
    Assignee: Schering Corporation
    Inventors: Kelvin H. Yong, Ilia A. Zavialov, Jianguo Yin, Xiaoyong Fu, Tiruvettipuram K. Thiruvengadam
  • Patent number: 7687527
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 30, 2010
    Assignee: Schering Corporation
    Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K. C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Umar Faruk Mansoor, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li
  • Patent number: 7687501
    Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: March 30, 2010
    Assignee: Schering Corporation
    Inventors: Chad E. Bennett, William J. Greenlee, Chad E. Knutson, Duane A. Burnett